



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

May 27, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434
Dear Sir (s),

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Sub: Outcome of Board Meeting held on May 27, 2026

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Wednesday, May 27, 2026, inter-alia considered and approved the following:

1. Audited Financial Results:

The Audited Financial Results for the Quarter and year ended March 31, 2026. A copy of the same is enclosed along with the Report of the Statutory Auditors thereon and a declaration signed by the Chief Financial Officer stating that the said report is with unmodified opinion.

2. Dividend:

Recommendation of Final Dividend of Re. 1.00 (Rupee 1.00) per equity share i.e. 50% on the face value of Rs. 2/- each, subject to approval of shareholders at the ensuing Annual General Meeting.

Ensuing Annual General Meeting of the Company shall be convened and held as per the directives and circulars issued by the relevant authorities and the details thereof shall be intimated separately.

The Meeting of the Board of Directors of the Company commenced at 03:45 p.m. and concluded at 06.00 p.m.

Kindly take the above information on your records.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Prachi Sathe

Company Secretary & Compliance Officer

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE

KAKARIA AND ASSOCIATES LLP

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B.Com., B.L., F.C.A.

SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B.Com., F.C.A.

AMAR J. BHANUSHALI B.Com., D.T.M., F.C.A.

VINAYAK P. BAFANA B.Com., F.C.A.

YOUR REF. :

OUR REF. :

INDEPENDENT AUDITOR'S REPORT ON THE AUDIT OF STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SUPRIYA LIFESCIENCE LIMITED

Opinion

We have audited the accompanying Statement of Standalone Financial Results of **SUPRIYA LIFESCIENCE LIMITED** ("the Company"), for the three months and year ended March 31st, 2026 ("the Statement"/"Standalone Financial Results"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financials statement:

- a. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- b. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the three months and year ended March 31st, 2026.
- c. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not

802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri West,

Mumbai - 400 053. Email: mumbai.kakaria@gmail.com,

Website: www.kakariaassociates.com



enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion

- d. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 14th October, 2021 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion

We conducted our audit of these Standalone Financial Results in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results under the provisions of the Act and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited Interim Condensed Standalone Financial Statements for the three months and year ended March 31st, 2026. The Company's Board of Directors are responsible for the preparation and presentation of the Standalone Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in the Ind AS 34 prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively, ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial

Cell



Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain Professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.




- Conclude on the appropriateness of the Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the Planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For,
Kakaria and Associates LLP
Chartered Accountants.
FRN: 104558W/ W100601


CA. Ujwal K. Kakaria
Partner
Membership No. – 035416
Place: - Mumbai



Date: - 27th May 2026

UDIN: - 26035416PHJBQM6305



SUPRIYA LIFESCIENCE LIMITED

CIN No: L51900MH2008PLC180452

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.

Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

(₹ In million)

Statement of Standalone Audited Financial Results for the Quarter and Year Ended March 31, 2026

Sr.No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended
		31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
		Audited	Unaudited	Audited	Audited	Audited
	Income					
I	Revenue from Operations	2,765.28	2,064.40	1,841.09	8,278.75	6,964.85
II	Other Income	34.78	26.11	29.75	114.87	98.15
III	Total Income	2,800.06	2,090.51	1,870.84	8,393.62	7,063.00
	Expenses					
	a) Cost of Materials Consumed	833.61	772.98	1,015.31	2,651.18	2,324.36
	b) Purchase of Stock in Trade	-	-	-	-	-
	c) Change in inventories of finished goods , work in progress & stock in trade.	219.66	(160.98)	(467.05)	(110.89)	(212.59)
	d. Employee benefit expenses	248.17	246.94	209.77	966.80	805.19
	e. Finance Cost	4.68	4.94	4.17	18.89	16.86
	f. Depreciation & amortisation expense	84.98	68.21	60.81	284.09	204.44
	g. Other expenditure	487.67	484.64	407.21	1,831.18	1,439.93
IV	Total Expenses	1,878.77	1,416.73	1,230.22	5,641.25	4,578.19
V	Profit/(loss) before Exceptional Items & Tax (III - IV)	921.29	673.78	640.62	2,752.37	2,484.81
VI	Exceptional Items	-	(4.58)	-	(4.58)	-
VII	Profit/(loss) before Tax (V-VI)	921.29	669.20	640.62	2,747.79	2,484.81
VIII	Tax Expense					
	a) Current Tax	204.16	153.24	127.72	614.33	566.57
	b) Deferred Tax	(25.16)	19.21	9.08	42.26	38.66
IX	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	742.29	496.75	503.82	2,091.20	1,879.58
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	742.29	496.75	503.82	2,091.20	1,879.58
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	0.55	0.54	1.16	(1.33)	(1.67)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	(0.14)	(0.14)	(0.29)	0.34	0.42
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	742.70	497.15	504.69	2,090.21	1,878.33
XVI	Earnings per equity Share (for continuing operation):					
	(1) Basic (In ₹)	9.22	6.17	6.29	25.98	23.35
	(2) Diluted (In ₹)	9.22	6.17	6.29	25.98	23.35
XVII	Earnings per equity Share (for discontinued operation):					
	(1) Basic (In ₹)	-	-	-	-	-
	(2) Diluted (In ₹)	-	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):					
	(1) Basic (In ₹)	9.22	6.17	6.29	25.98	23.35
	(2) Diluted (In ₹)	9.22	6.17	6.29	25.98	23.35

[Handwritten Signature]




See accompanying notes to the financial statements:

Notes:-

1. The audited standalone financial results of the Company for the quarter ended March 31, 2026 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.
2. The above audited standalone financial results of the Company for the quarter ended March 31, 2026 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on May 27, 2026.
3. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes, among other things, setting a uniform definition of wages. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations.
The Company has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs. 4.58 millions towards employee benefits during the year ended March 31, 2026. The Company continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules there to and the impact of these will be accounted in accordance with applicable accounting standards.
4. The Company has adopted Ind AS 116 "Leases" effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019.
5. The Board of Directors at their meeting dated May 27, 2026 has recommended a final dividend of INR 1/- per equity share (50% on the face value INR 2/- each), subject to approval of shareholders at the ensuing Annual General Meeting.
6. The company does not have any subsidiary/associate/joint venture company as on March 31, 2026.
7. The figures of the previous periods have been regrouped wherever necessary to confirm to the current period presentation.
8. The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the relevant financial year. Also the figures up to the end of third quarter were only reviewed and not subjected to audit.

Place :- Mumbai
Date :- May 27, 2026

For Supriya Lifescience Limited



Dr. Satish Waman Wagh
Chairman and Executive Director
DIN: 01456982



SUPRIYA LIFESCIENCE LIMITED

CIN No: L51900MH2008PLC180452

Standalone Balance Sheet as at March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	March 31, 2026	March 31, 2025
ASSETS		
Non-current assets		
(a) Property, plant and equipment	6,833.17	4,468.32
(b) Right to Use Asset	45.23	46.45
(c) Capital Work in progress	355.48	1,480.15
(d) Intangible Assets	13.12	13.89
(e) Financial Assets		-
(i) Investments	985.23	632.41
(ii) Loans and Advances	-	-
(f) Other Non- Current Assets	15.81	111.54
Total Non-current assets	8,248.04	6,752.76
Current assets		
(a) Inventories	1,595.97	1,183.49
(b) Financial Assets		-
(i) Loans and Advances	5.69	9.27
(ii) Trade receivables	2,194.48	1,343.62
(iii) Cash and cash equivalents	375.46	760.57
(iv) Bank balances other than (iii) above	413.21	30.97
(v) Other Financial Assets	-	7.11
(c) Other current assets	738.22	1,085.68
Total Current Assets	5,323.03	4,420.71
TOTAL ASSETS	13,571.07	11,173.47
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity share capital	160.97	160.97
(b) Other equity	11,816.36	9,806.63
Total Equity	11,977.33	9,967.60
LIABILITIES		
Non-current liabilities		
(a) Financial Liabilities		
(i) Lease Liabilities	51.89	50.57
(ii) Other financial liabilities	-	-
(b) Provisions	18.97	13.18
(c) Deferred tax Liabilities	312.44	270.18
Total Non-Current Liabilities	383.30	333.93
Current liabilities		
(a) Financial liabilities		
(i) Lease Liabilities	2.46	3.23
(ii) Trade payables		
- Micro Enterprises and Small Enterprises	170.01	-
- Other than micro and small enterprises	938.46	745.46
(iii) Other financial liabilities	20.40	17.59
(b) Provisions	16.71	11.93
(c) Other current liabilities	62.40	93.73
Total Current Liabilities	1,210.44	871.94
TOTAL EQUITY AND LIABILITIES	13,571.07	11,173.47



SUPRIYA LIFESCIENCE LIMITED

CIN No: L51900MH2008PLC180452

Cash flow statement for the period ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	March 31, 2026	March 31, 2025
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	2,747.79	2,484.80
Adjustments for		
Depreciation and Amortization	284.09	204.44
Interest Income (Net of Expenses)	(94.54)	(78.85)
Dividend Received	(0.00)	(0.05)
Employee Benefit	9.24	11.75
Loss on Sale of fixed Assets	0.09	0.06
Operating profit before working capital changes	2,946.67	2,622.15
Adjustments for movement in working capital		
Adjustments for (increase)/ decrease in operating assets		
Trade Receivables	(850.85)	(226.79)
Inventories	(412.48)	(331.00)
Other Non Current & Current Assets	443.18	67.15
Other Non Current & Current Financial Assets	7.11	37.97
Loans and Advances	3.58	(0.30)
	(809.46)	(452.97)
Adjustments for increase/ (decrease) in operating liabilities		
Trade payables	363.01	149.76
Other Non Current & Current Financial Liabilities	2.80	1.85
Other Non Current & Current liabilities	(31.34)	(82.25)
	334.47	69.36
(Income tax paid)/net of refund	(613.99)	(591.79)
Net Cash generated from Operating Activities (A)	1,857.69	1,646.75
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(1,522.35)	(1,623.76)
(Purchase)/ Sale of Investments	(352.82)	5.56
Interest Income	113.43	95.71
Dividend Received	0.00	0.05
Net Cash generated/(outflow) from Investing Activities (B)	(1,761.74)	(1,522.44)
C CASH FLOW FROM FINANCING ACTIVITIES		
Increase/(Decrease) in Long term borrowings	-	-
Increase/(Decrease) in Short term borrowing	-	-
Finance Cost	(18.89)	(16.86)
Dividend Paid	(80.48)	(64.39)
Repayment of Lease liability	0.55	(1.08)
Net Cash generated from Financing Activities (C)	(98.82)	(82.33)
Net Increase/(Decrease) in Cash and Cash equivalents (A+B+C)	(2.87)	41.98
Cash and Cash Equivalents at the end of previous period	791.54	749.56
Cash and Cash Equivalents as at the end of the reporting period	788.67	791.54





SUPRIYA LIFESCIENCE LTD.

Creating true values that binds global health

May 27, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Dear Sir (s),

Sub: Declaration pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In terms of the provisions of Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we confirm that the Statutory Auditors of the Company, M/s. Kakaria & Associates LLP, Chartered Accountants (FRN: 104558W/W100601) have issued an Audit Report with unmodified opinion in respect of Audited Financial Results of the Company for the year ended March 31, 2026 as approved by the Board at its meeting held today i.e. May 27, 2026.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Krishna Raghunathan
Chief Financial Officer

